Non-canonical PD-1 signaling in cancer and its potential implications in clinic
| العنوان: | Non-canonical PD-1 signaling in cancer and its potential implications in clinic |
|---|---|
| المؤلفون: | Juan An, Ying Jiang, Wei Zhao, Xiaochun Zhang, Xi Wang, Huoming Chen, Jin Shang, Zhihua Li, Bo Zhu, Haoran Zha, Lei Yu, Li Zhaoxia, Ning Wang |
| المصدر: | Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021) Journal for Immunotherapy of Cancer |
| بيانات النشر: | BMJ Publishing Group, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, Cell type, tumor, medicine.medical_treatment, Immunology, Programmed Cell Death 1 Receptor, Review, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, medicine, Tumor Microenvironment, Immunology and Allergy, Cytotoxic T cell, Humans, Immune Checkpoint Inhibitors, RC254-282, Pharmacology, Tumor microenvironment, biology, business.industry, Cancer, biomarkers, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Immunotherapy, medicine.disease, Blockade, Gene Expression Regulation, Neoplastic, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer cell, Cancer research, biology.protein, Molecular Medicine, immunotherapy, Antibody, business, Signal Transduction |
| الوصف: | Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cancers. However, only a certain group of patients benefit from PD-1 blockade therapy and many patients succumb to hyperprogressive disease. Although, CD8 T cells and conventional T cells are generally considered to be the primary source of PD-1 in cancer, accumulating evidence suggests that other distinct cell types, including B cells, regulatory T cells, natural killer cells, dendritic cells, tumor-associated macrophages and cancer cells, also express PD-1. Hence, the response of patients with cancer to PD-1 blockade therapy is a cumulative effect of anti-PD-1 antibodies acting on a myriad of cell types. Although, the contribution of CD8 T cells to PD-1 blockade therapy has been well-established, recent studies also suggest the involvement of non-canonical PD-1 signaling in blockade therapy. This review discusses the role of non-canonical PD-1 signaling in distinct cell types and explores how the available knowledge can improve PD-1 blockade immunotherapy, particularly in identifying novel biomarkers and combination treatment strategies. |
| اللغة: | English |
| تدمد: | 2051-1426 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3adcf2ab23d13bb7b4fb866b5550fb4cTest https://jitc.bmj.com/content/9/2/e001230.fullTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....3adcf2ab23d13bb7b4fb866b5550fb4c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20511426 |
|---|